IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2024
Aggregated presentation by day and by market
Statement of transactions in own shares from June 3 to June 7, 2024 | ||||||
Name of issuer | Identification code of issuer (Legal Entity Identifier) | Day of transaction | Identification code of financial instrument | Aggregated daily volume (in number of shares) | Daily weighted average price of the purchased shares * | Market (MIC Code) |
IPSEN | 549300M6SGDPB4Z94P11 | 03/06/2024 | FR0010259150 | 3 100 | 120,9943 | XPAR |
IPSEN | 549300M6SGDPB4Z94P11 | 04/06/2024 | FR0010259150 | 3 100 | 121,5713 | XPAR |
IPSEN | 549300M6SGDPB4Z94P11 | 05/06/2024 | FR0010259150 | 3 100 | 122,2187 | XPAR |
IPSEN | 549300M6SGDPB4Z94P11 | 06/06/2024 | FR0010259150 | 3 500 | 122,5593 | XPAR |
IPSEN | 549300M6SGDPB4Z94P11 | 07/06/2024 | FR0010259150 | 5 000 | 123,1718 | XPAR |
TOTAL | 17 800 | 122,2274 | ||||
17 800 |
Attachment
IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2024
- 11 June 2024 - 1 mins read
Aggregated presentation by day and by market
Statement of transactions in own shares from June 3 to June 7, 2024 | ||||||
Name of issuer | Identification code of issuer (Legal Entity Identifier) | Day of transaction | Identification code of financial instrument | Aggregated daily volume (in number of shares) | Daily weighted average price of the purchased shares * | Market (MIC Code) |
IPSEN | 549300M6SGDPB4Z94P11 | 03/06/2024 | FR0010259150 | 3 100 | 120,9943 | XPAR |
IPSEN | 549300M6SGDPB4Z94P11 | 04/06/2024 | FR0010259150 | 3 100 | 121,5713 | XPAR |
IPSEN | 549300M6SGDPB4Z94P11 | 05/06/2024 | FR0010259150 | 3 100 | 122,2187 | XPAR |
IPSEN | 549300M6SGDPB4Z94P11 | 06/06/2024 | FR0010259150 | 3 500 | 122,5593 | XPAR |
IPSEN | 549300M6SGDPB4Z94P11 | 07/06/2024 | FR0010259150 | 5 000 | 123,1718 | XPAR |
TOTAL | 17 800 | 122,2274 | ||||
17 800 |
Attachment
Related Press Releases
07 November 2024
1 mins read
Ipsen – October 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
09 October 2024
1 mins read
Ipsen – September 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
18 September 2024
9 mins read
Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors
16 September 2024
9 mins read
Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors
15 September 2024
7 mins read
Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis
04 September 2024
1 mins read
Ipsen – August 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
30 August 2024
1 mins read
Testing video 1
30 August 2024
1 mins read
Testing video 3
30 August 2024
1 mins read
Testing video 2
13 August 2024
1 mins read